HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Higuchi, K. Articles by Takeda, T. Search for Related Content PubMed PubMed Citation Articles by Higuchi, K. Articles by Takeda, T. Social Bookmarking                      What's this?

Journal of Lipid Research, Vol 33, 1753-1764, Copyright © 1992 by Lipid Research, Inc.

ARTICLES

Developmental and age-related changes in apolipoprotein B mRNA editing in mice

K Higuchi, K Kitagawa, K Kogishi and T Takeda
Department of Senescence Biology, Kyoto University, Japan.

Apolipoprotein B (apoB) mRNA is modified by a post-transcriptional editing reaction (C to U) changing a glutamine (CAA) to a translational stop codon (UAA) and producing apoB-48 mRNA in mammalian liver and intestine. Developmental and age-related changes in apoB mRNA editing were studied using two mouse strains with different aging processes (SAM-R/1 with a normal aging process and SAM-P/1 with an accelerated aging process). During growth of both strains, the proportion of unedited (apoB-100) mRNA decreased from 80% in the fetal liver at the 17th day of gestation to 30% in the liver of mature 2-month-old mice. Age-associated increase in the proportion of hepatic apoB-100 mRNA was observed from the age of 18 months in the SAM-R/1 strain. In the SAM- P/1 strain, apoB-100 mRNA in the liver continued to increase from the age of 10 months to death. The profiles of developmental and age- related changes in the proportion of two serum apoB isoproteins (apoB- 100 and apoB-48) followed the extent of hepatic apoB mRNA editing. Age- related changes in the extent of apoB mRNA editing in the small intestine were not observed in either strain. A slight expression of apoB was detected by reverse transcriptase-polymerase chain reaction in the kidney, stomach, and colon, and age-associated change in the extent of editing was observed in the kidney. These correlated changes in apoB mRNA editing and serum apoB proteins suggest that RNA editing may be one mechanism involved in the regulation of lipoprotein biogenesis in biological development and in senescent mice. An age-associated decrease in the extent of hepatic apoB mRNA editing and increases of the proportion of serum apoB-100 protein were observed in senescent mice.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				R. P. Bennett, V. Presnyak, J. E. Wedekind, and H. C. Smith Nuclear Exclusion of the HIV-1 Host Defense Factor APOBEC3G Requires a Novel Cytoplasmic Retention Signal and Is Not Dependent on RNA Binding J. Biol. Chem., March 21, 2008; 283(12): 7320 - 7327. [Abstract] [Full Text] [PDF]

				T. Iwaki, M. J. Sandoval-Cooper, M. Brechmann, V. A. Ploplis, and F. J. Castellino A fibrinogen deficiency accelerates the initiation of LDL cholesterol-driven atherosclerosis via thrombin generation and platelet activation in genetically predisposed mice Blood, May 15, 2006; 107(10): 3883 - 3891. [Abstract] [Full Text] [PDF]

				X. Lin, P. Yue, Y. Xie, N. O. Davidson, N. Sakata, R. E. Ostlund Jr., Z. Chen, and G. Schonfeld Reduced intestinal fat absorptive capacity but enhanced susceptibility to diet-induced fatty liver in mice heterozygous for ApoB38.9 truncation Am J Physiol Gastrointest Liver Physiol, July 1, 2005; 289(1): G146 - G152. [Abstract] [Full Text] [PDF]

				A. Schiopu, J. Bengtsson, I. Soderberg, S. Janciauskiene, S. Lindgren, M. P.S. Ares, P. K. Shah, R. Carlsson, J. Nilsson, and G. N. Fredrikson Recombinant Human Antibodies Against Aldehyde-Modified Apolipoprotein B-100 Peptide Sequences Inhibit Atherosclerosis Circulation, October 5, 2004; 110(14): 2047 - 2052. [Abstract] [Full Text] [PDF]

				G. N. Fredrikson, I. Soderberg, M. Lindholm, P. Dimayuga, K.-Y. Chyu, P. K. Shah, and J. Nilsson Inhibition of Atherosclerosis in ApoE-Null Mice by Immunization with ApoB-100 Peptide Sequences Arterioscler. Thromb. Vasc. Biol., May 1, 2003; 23(5): 879 - 884. [Abstract] [Full Text] [PDF]

				Z. Chen, R. L. Fitzgerald, J. E. Saffitz, C. F. Semenkovich, and G. Schonfeld Amino Terminal 38.9% of Apolipoprotein B-100 Is Sufficient to Support Cholesterol-Rich Lipoprotein Production and Atherosclerosis Arterioscler. Thromb. Vasc. Biol., April 1, 2003; 23(4): 668 - 674. [Abstract] [Full Text] [PDF]

				A. P. Patterson, Z. Chen, D. C. Rubin, V. Moucadel, J. L. Iovanna, H. B. Brewer Jr., and T. L. Eggerman Developmental Regulation of Apolipoprotein B mRNA Editing Is an Autonomous Function of Small Intestine Involving Homeobox Gene Cdx1 J. Biol. Chem., February 21, 2003; 278(9): 7600 - 7606. [Abstract] [Full Text] [PDF]

				D. Mukhopadhyay, M. Plateroti, S. Anant, F. Nassir, J. Samarut, and N. O. Davidson Thyroid Hormone Regulates Hepatic Triglyceride Mobilization and Apolipoprotein B Messenger Ribonucleic Acid Editing in a Murine Model of Congenital Hypothyroidism Endocrinology, February 1, 2003; 144(2): 711 - 719. [Abstract] [Full Text] [PDF]

				M. E. Hinsdale, P. M. Sullivan, H. Mezdour, and N. Maeda ApoB-48 and apoB-100 differentially influence the expression of type-III hyperlipoproteinemia in APOE*2 mice J. Lipid Res., September 1, 2002; 43(9): 1520 - 1528. [Abstract] [Full Text] [PDF]

				E. Voyiaziakis, C. Ko, S. M. O'Rourke, and L.-S. Huang Genetic control of hepatic apoB-100 secretion in human apoB transgenic mouse strains J. Lipid Res., November 1, 1999; 40(11): 2004 - 2012. [Abstract] [Full Text]

				E. Kim and S. G. Young Genetically modified mice for the study of apolipoprotein B J. Lipid Res., April 1, 1998; 39(4): 703 - 723. [Abstract] [Full Text] [PDF]

				P. Tarugi, G. Ballarini, B. Pinotti, A. Franchini, E. Ottaviani, and S. Calandra Secretion of apoB- and apoA-I-containing lipoproteins by chick kidney J. Lipid Res., April 1, 1998; 39(4): 731 - 743. [Abstract] [Full Text]

				W. A. Boisvert, J. Spangenberg, and L. K. Curtiss Role of Leukocyte-Specific LDL Receptors on Plasma Lipoprotein Cholesterol and Atherosclerosis in Mice Arterioscler. Thromb. Vasc. Biol., February 1, 1997; 17(2): 340 - 347. [Abstract] [Full Text]

				B. J.M. van Vlijmen, K. W. van Dijk, H. B. van't Hof, P. J.J. van Gorp, A. van der Zee, H. van der Boom, M. L. Breuer, M. H. Hofker, and L. M. Havekes In the Absence of Endogenous Mouse Apolipoprotein E, Apolipoprotein E*2(Arg-158 right-arrow Cys) Transgenic Mice Develop More Severe Hyperlipoproteinemia than Apolipoprotein E*3-Leiden Transgenic Mice J. Biol. Chem., November 29, 1996; 271(48): 30595 - 30602. [Abstract] [Full Text] [PDF]

				K.-I. Hirano, S. G. Young, R. V. Farese Jr., J. Ng, E. Sande, C. Warburton, L. M. Powell-Braxton, and N. O. Davidson Targeted Disruption of the Mouse apobec-1 Gene Abolishes Apolipoprotein B mRNA Editing and Eliminates Apolipoprotein B48 J. Biol. Chem., April 26, 1996; 271(17): 9887 - 9890. [Abstract] [Full Text] [PDF]

				Z. Chen, R. L. Fitzgerald, M. R. Averna, and G. Schonfeld A Targeted Apolipoprotein B-38.9-producing Mutation Causes Fatty Livers in Mice Due to the Reduced Ability of Apolipoprotein B-38.9 to Transport Triglycerides J. Biol. Chem., October 13, 2000; 275(42): 32807 - 32815. [Abstract] [Full Text] [PDF]